• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolecarboxylic acids and derivatives Indolecarboxylic acids

Research Brief on 1-Benzyl-1H-indole-4-carboxylic acid (CAS: 860360-11-8) in Chemical Biology and Pharmaceutical Applications

1-Benzyl-1H-indole-4-carboxylic acid (CAS: 860360-11-8) is a structurally unique indole derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound, characterized by its benzyl substitution at the 1-position and carboxylic acid functional group at the 4-position of the indole scaffold, exhibits versatile pharmacological properties. Recent studies have explored its potential as a key intermediate in drug discovery, particularly in the development of small-molecule modulators targeting inflammatory pathways and enzyme inhibition.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 1-Benzyl-1H-indole-4-carboxylic acid serves as a privileged scaffold for designing potent inhibitors of cyclooxygenase-2 (COX-2), with improved selectivity over COX-1. The research team utilized structure-activity relationship (SAR) analysis to optimize the compound's anti-inflammatory profile while minimizing gastrointestinal toxicity. Molecular docking studies revealed that the benzyl group at the 1-position and the carboxylic acid at the 4-position create critical interactions with the COX-2 active site, explaining the observed selectivity.

In parallel developments, pharmaceutical researchers have investigated 860360-11-8 as a building block for novel kinase inhibitors. A recent patent application (WO2023056421) disclosed derivatives of 1-Benzyl-1H-indole-4-carboxylic acid showing promising activity against JAK3 kinase, with IC50 values in the low micromolar range. The carboxylic acid moiety was found to participate in key hydrogen bonding interactions with the kinase's hinge region, while the benzyl group contributed to improved cellular permeability.

From a synthetic chemistry perspective, innovative routes to 1-Benzyl-1H-indole-4-carboxylic acid have been developed to support scaled-up production. A 2024 Organic Process Research & Development publication described a continuous flow chemistry approach that achieves 78% yield with excellent purity (>99%), addressing previous challenges in the large-scale preparation of this intermediate. The methodology features a novel palladium-catalyzed benzylation step followed by selective carboxylation.

Emerging applications in chemical biology have expanded the utility of 860360-11-8 beyond traditional drug discovery. Recent work in Chemical Science (2024) demonstrated its use as a versatile scaffold for developing fluorescent probes targeting G-protein-coupled receptors (GPCRs). The indole core's inherent fluorescence properties, combined with the modifiable carboxylic acid group, enabled the creation of environment-sensitive probes for studying receptor conformational changes in live cells.

Safety and toxicology profiling of 1-Benzyl-1H-indole-4-carboxylic acid has progressed significantly, with a comprehensive ADMET study published in Xenobiotica (2023) reporting favorable pharmacokinetic properties. The compound showed good metabolic stability in human liver microsomes (t1/2 > 120 minutes) and minimal inhibition of major CYP450 enzymes, suggesting a low potential for drug-drug interactions in therapeutic applications.

Looking forward, the unique structural features of 860360-11-8 continue to inspire novel research directions. Current investigations are exploring its potential in PROTAC (proteolysis targeting chimera) design, where the carboxylic acid group serves as an ideal attachment point for E3 ligase ligands. Preliminary results presented at the 2024 ACS Spring Meeting show promising degradation efficiency for several challenging protein targets.

• 27018-76-4(1-benzyl-1H-indole-3-carboxylic acid)
• 263021-42-7(1-Ethyl-1H-indole-5-carboxylic acid)
• 1030423-79-0(1-Benzyl-1H-indole-6-carboxylic acid)
• 3215-45-0(9-Ethyl-9H-carbazole-3,6-dicarboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)